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Introduction: The locus coeruleus noradrenergic (LC-NA) system is studied for its role
in various neurological and psychiatric disorders such as epilepsy and Major Depression
Dissorder. Chemogenetics is a powerful technique for specific manipulation of the LC
to investigate its functioning. Local injection of AAV2/7 viral vectors has limitations
with regards to efficiency and specificity of the transduction, potentially due to low
tropism of AAV2/7 for LC neurons. In this study we used a canine adenovirus type
2 (CAV2) vector with different volumes and viral particle numbers to achieve high and
selective expression of hM3Dq, an excitatory Designer Receptor Exclusively Activated
by Designer Drugs (DREADD), for chemogenetic modulation of LC neurons.
Methods: Adult male Sprague-Dawley rats were injected in the LC with different
absolute numbers of CAV2-PRSx8-hM3Dq-mCherry physical particles (0.1E9, 1E9,
5E9,10E9, or 20E9 pp) using different volumes (LowV = 3 nl × 300 nl,
MediumV = 3 × 600 nl, HighV = 3 × 1200 nl). Two weeks post-injection, double-
labeling immunohistochemistry for dopamine β hydroxylase (DBH) and mCherry
was performed to determine hM3Dq expression and its specificity for LC neurons.
The size of the transduced LC was compared to the contralateral LC to identify
signs of toxicity.
Results: Administration of Medium volume (3 × 600 nl) and 1E9 particles resulted
in high expression levels with 87.3 ± 9.8% of LC neurons expressing hM3Dq,
but low specificity with 36.2 ± 17.3% of hM3Dq expression in non-LC neurons.
The most diluted conditions (Low volume_0.1E pp and Medium Volume_0.1E pp)
presented similar high transduction of LC neurons (70.9 ± 12.7 and 77.2 ± 9.8%)
with lower aspecificity (5.5 ± 3.5 and 4.0 ± 1.9%, respectively). Signs of toxicity
were observed in all undiluted conditions as evidenced by a decreased size of the
transduced LC.
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Conclusion: This study identified optimal conditions (Low and Medium Volume with
0.1E9 particles of CAV2-PRSx8-hM3Dq-mCherry) for safe and specific transduction
of LC neurons with excitatory DREADDs to study the role of the LC-NA system in
health and disease.
Keywords: locus coeruleus, chemogenetics, designer receptor exclusively activated by designer drugs, canine
associated viral vector, neurological disorder
INTRODUCTION
Through its widespread projections, the locus coeruleus (LC)–
noradrenaline (NA) system modulates cortical, subcortical,
cerebellar, brainstem, and spinal cord neuronal circuits
influencing important physiological functions such as sleep,
attention, memory, cognitive control and neuroplasticity
(Samuels and Szabadi, 2008a,b; Szabadi, 2013). The LC-NA
system is studied for its role in various neurological disorders
such a depression, Parkinson’s disease, Alzheimer’s disease and
epilepsy (Raedt et al., 2011; Grimonprez et al., 2015; Mather and
Harley, 2016; Bari et al., 2020). Chemogenetics is a technique
to specifically modulate brain structures and/or neuronal
phenotypes using Designer Receptors Exclusively Activated by
Designer Drugs (DREADDs) and greatly facilitates studying their
contribution to behavior and disease. DREADDs are genetically
modified G-protein coupled receptors inert for the endogenous
ligand acetylcholine and activated by “designer drugs” such
as Clozapine-N-Oxide (CNO), clozapine, deschloroclozapine
(DCZ), compound 21 or JHU37152 and JHU37160 (Gomez
et al., 2017; Bonaventura et al., 2019; Jendryka et al., 2019;
Nagai et al., 2020).
A frequently used method to induce expression of DREADDs
in LC neurons consists of injecting a viral vector, such as the
adeno-associated virus (AAV) vector or canine adenovirus type
2 (CAV2) vector, in the LC region or its projection targets
(Vazey and Aston-Jones, 2014; Hirschberg et al., 2017). Using
PRSx8, a synthetic dopamine-β-hydroxylase (DBH) promotor,
LC-specific DREADD expression is achieved (Hwang et al.,
2001; Vazey and Aston-Jones, 2014). Apart from the type of
viral vector and the promotor sequence, parameters such as
injection site, volume and the amount of viral vector particles
define cell-specific expression and specificity (Castle et al., 2016;
Delbeke et al., 2017).
In this study, we compared different conditions for injecting
CAV2-PRSx8-hM3Dq-mCherry viral vector in the LC to induce
expression of the excitatory DREADD, hM3Dq, specifically in
LC neurons. Our previous results demonstrated low cell-specific
expression and specificity using the AAV2/7-PRSx8-hM3Dq-
mCherry. We hypothesized that this is due to low tropism of
the AAV2/7 viral particle for LC noradrenergic cells (Stevens
et al., 2020). The CAV2 viral vector has been proven to efficiently
transduce neurons by uptake both at the cell body and at the
axonal terminals (Kremer et al., 2000; Soudais et al., 2000; Junyent
and Kremer, 2015; Del Rio et al., 2019) and is validated to
target the LC (Li et al., 2016; Hirschberg et al., 2017; Hayat
et al., 2020). Pickering et al. demonstrated that CAV2 vectors
containing the PRSx8 promotor can transduce LC neurons with
high efficiency via direct or retrograde administration for opto-
activation experiments (Li et al., 2016). However, Hayat et al.
(2020) observed a substantial lower level of GtACR2 expression
when compared to ChR2 using identical injection parameters.
This indicates that transduction efficiency is amongst other
factors dependent on the transgene itself. Additionally, to our
knowledge no study describes the use of CAV2 carrying a plasmid
to express the excitatory hM3Dq DREADD receptor. Since the
transgene sequence itself can influence transduction efficiency,
a reliable viral vector administration protocol is required when
introducing a novel genetically modified receptor (Wang et al.,
2019). When injecting a novel viral vector into a target area, safety
of the administration has to be assessed, since viral vectors can
induce toxicity with consequent cell loss (Sen et al., 2014).
By testing different injection volumes and numbers of CAV2-
PRSx8-hM3Dq-mCherry viral vector particles to obtain optimal
transduction efficiency with minimal aspecificity and toxicity in
the LC of adult rats, we aim to achieve a condition where cell-
specific modulation of the LC is feasible to study its role in
regulating excitability of neural pathways.
MATERIALS AND METHODS
Animals
Adult male Sprague-Dawley rats (Envigo, The Netherlands) were
used in this study and treated according to European guidelines
(directive 2010/63/EU). The local Ethical Committee on Animal
Experiments of Ghent University (ECD 16/31) approved the
study protocol. Animals were kept under environmentally
controlled conditions: 12 h light/dark cycles with artificially
dimmed light, temperature and relative humidity at 20–23◦C and
40–60%, respectively, with food (Rats and Mice Maintenance,
Carfil, Belgium) and water ad libitum. All animals were group-
housed in Type IV cages (Tecniplast, Australia) on wood-based
bedding (Carfil, Belgium). Cages were enriched with paper
nesting material and cardboard tunnels (Carfil, Belgium).
Viral Vector Administration
Animals (n = 43; 10–11 weeks old; 371 ± 72 g body
weight) were anesthetized with a mixture of medical oxygen
and isoflurane (5% for induction, 2% for maintenance, Isoflo,
Zoetis, United Kingdom); body temperature was controlled
using a heating pad. Rats were placed in a stereotaxic frame
(Stoelting, United States) and the skull was exposed. Bregma
was lowered 2 mm relative to lambda (15◦ head angle) to
target the LC and avoid the transverse sinus. Using a Hamilton
Neuros Syringe (Hamilton company, Nevada, United States) and
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Quintessential Stereotaxic Injection system (flowrate 150 nl/min,
Stoelting, United States), three injections of CAV2-PRSx8-
hM3Dq-mCherry vector solutions [5.9 × 109 pp/µl undiluted,
in phosphate-buffered saline (PBS)] were performed along the
dorsoventral axis in the LC (3.9 AP, 1.15 ML relative to lambda,
−5.8, −5.5, −5.3 DV from dura). The following injection
conditions were tested: 3 × 300 nl containing 5E9 pp of
CAV2 (LowV_5E9, n = 7, unilateral), 3 × 600 nl containing
10E9 pp CAV2 (MediumV_10E9, n = 8, unilateral), 3 × 1,200 nl
containing 20E9 pp CAV2 (HighV_20E9, n = 5, unilateral),
3 × 300 nl containing 1E9 pp of CAV2 (LowV_1E9, n = 8,
bilateral n = 5), 3 × 600 nl containing 1E9 pp CAV2
(MediumV_1E9, n = 6, unilateral), 3 × 300 nl containing
0.1E9 pp CAV2 (LowV_0.1E9, n = 4, bilateral) and 3 × 600 nl
containing 0.1E9 pp of CAV2 (MediumV_0.1E9, n = 5, bilateral;
Table 1).
After each injection the syringe was left in place for
an additional 5 min and then slowly retracted to avoid
backflow. Two-component silicone gel (Kwik-Sil; World
Precision Instruments, FL, United States) was applied to
the craniotomy to protect the brain surface. After surgery,
animals were subcutaneously (sc) injected with the non-
steroidal anti-inflammatory drug meloxicam (1 mg/kg metacam,
Boehringer Ingelheim, Germany) and lidocaine (5% Xylocaine
gel, Astrazeneca, United Kingdom) was applied to the incision
site to minimize discomfort. All animals recovered 2 weeks in
their home cage to allow for optimal viral vector expression
(Smith et al., 2016).
Histology
Tissue Collection and Fixation
Animals were euthanized 2 weeks after viral vector injections
with an overdose of sodium pentobarbital (200 mg/kg, i.p.)
followed by a transcardial perfusion with PBS and subsequent
paraformaldehyde (4%, pH 7.4). The brains were post-fixed in
paraformaldehyde for 24 h and subsequently cryoprotected in
a sucrose solution of 10% (1 day), 20% (±2 days), and 30%
(±3 days) at 4◦C until saturation was achieved, snap-frozen in
isopentane and stored in liquid nitrogen at −196◦C. After 1 h at
−20◦C, tissue was transferred to a Cryostat (Leica, Germany) and
coronal cryosections of 40 µm were made.
TABLE 1 | Overview of the different conditions: volume and number of physical
viral particles.
Group ID # Animals Volume # Viral particles Titer
LowV_0.1E9 3 3 × 300 nl 0.1 × 109 ∼0.55 × 108 pp/µl
MediumV_0.1E9 5 3 × 600 nl 0.1 × 109 ∼1.1 × 108 pp/µl
LowV_1E9 7 3 × 300 nl 1 × 109 ∼0.55 × 109 pp/µl
MediumV_1E9 5 3 × 600 nl 1 × 109 ∼1.1 × 109 pp/µl
LowV_5E9 7 3 × 300 nl 5 × 109 ∼5.9 × 109 pp/µl
MediumV_10E9 7 3 × 600 nl 10 × 109 ∼5.9 × 109 pp/µl
HighV_20E9 5 3 × 1,200 nl 20 × 109 ∼5.9 × 109 pp/µl
The number of animals included in the analysis, without the four animals showing
no clear hM3Dq expression (LowV_0.1E9 group, n = 1; LowV_1E9, n = 1;
MediumV_10E9 group, n = 1; MediumV_1E9 group, n = 1).
Immunofluorescence Staining
Double label immunostaining for DBH and the mCherry tag
fused to the hM3Dq receptor was performed to quantify
specificity of hM3Dq expression, and evaluate possible damage
to the LC. Twelve histological sections were selected per animal
starting approximately 10.5 mm posterior to bregma, and keeping
every third section (80 µm apart), toward anterior. Selected
sections were rinsed twice for 5 min in distilled water (dH2O)
followed by incubation in 0.5 and 1% H2O2 for 30 and 60 min,
respectively, to block endogenous peroxidase activity. After
washing twice for 5 min in PBS, sections were incubated for
45 min in blocking buffer (BB; 0.4% Fish Skin Gelatin (FSG)
and 0.2% Triton X in PBS). For 1 h at room temperature and
subsequently overnight at 4◦C, sections were incubated in BB
with primary antibodies to visualize noradrenergic LC neurons
(mouse anti-DBH, 1:1000, clone 4F10.2, Merck) and mCherry
tag (rabbit anti-red fluorescent protein, 1:1000, ROCK600-901-
379, Rockland). The next day, sections were washed twice in BB
for 10 min followed by 1 h incubation in BB with the secondary
antibodies Alexa Fluor goat anti-mouse 488 nm (1:1000, Ab
150113, Abcam) and Alexa goat anti-rabbit 594 nm (1:1000, Ab
150176, Abcam) diluted in BB for 1 h. After washing twice in
PBS for 5 min, a nuclear DAPI stain was performed. After two
additional washing steps in PBS (2 × 5 min), sections were
mounted on glass slides and cover slipped using Vectashield
H1000 mounting medium (Vector Laboratories, United States)
to prevent photobleaching.
Fluorescence Microscopy and Image Analysis
Glass slides were scanned using a Pannoramic 250 slide scanner
equipped with a Plan Apochromat 40X objective and a pco.edge
4.2 4 MP camera to have overview images of all sections. Detailed
images of the LC sections were acquired using the Olympus IX81
confocal microscope using Olympus Fluoview FV1000 software
or a Nikon A1R confocal laser scanning microscope (Nikon
Benelux, Brussels, Belgium) equipped with a Plan Apo VC 20X,
0.75 NA objective lens (Nikon). Images were exported as .nd2 and
tiff files for post-processing.
For each rat, images of three tissue sections containing a
clear LC nucleus were selected to qualitatively identify the
presence and location of the hM3Dq expression. In bilaterally
injected animals, both hemispheres were checked for expression
and the first injected hemisphere was selected for further
analysis, since this resembles the unilateral injected conditions.
To assess possible signs of toxicity, in unilaterally injected
animals, the injected LC was compared to the contralateral
non-injected LC. Quantitative analysis in bilaterally injected
animals was only performed in animals showing unilateral
expression of the DREADD, to be able to compare the size of the
DREADD-expressing versus the non-expressing LC. Bilaterally
DREADD expressing animals were qualitatively assessed for
signs of toxicity. Post-processing analysis was performed in Fiji
ImageJ Software.
To determine cell-specific expression levels, hM3Dq-DBH
colocalization was quantified by placing virtual markers on
merged DBH+/DAPI images to identify the LC cells. These
markers were then copied on the merged DBH+/mCherry
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FIGURE 1 | Representative visualization of hM3Dq expression pattern in LC after injection of CAV2-PRSx8-hM3Dq-mCherry in LC for each condition. Each row
represents a condition. The first column represents an overview of an LC containing tissue section; the second column shows a more detailed view of hM3Dq
expression in the region of LC. The last column shows a confocal image of DBH+/hM3Dq+ cells. LC is encircled with a dashed line. Aspecific hM3Dq expression is
indicated by a white arrow. Ectopic DBH expression is indicated by the dotted line. LC-NA neurons and projections are visualized using primary anti-DBH antibody
(green, AF 488 nm) and expression of hM3Dq DREADD is visualized using anti-RFP (red, AF 594 nm), cell nuclei are stained with DAPI (blue). Scale bar is
represented at each image, left column 1,000 µm, middle column 500 µm and right column 25 µm.
images to determine the fraction of LC cells expressing hM3Dq-
mCherry. To determine % aspecific hM3Dq expression, the total
number of mCherry+ pixels were counted (# of white pixels after
“selection of all pixels” and “invert” command on the 8-bit trict
TIFF file), minus the ones present in the manually encircled LC
and then divided by the total number of mCherry+ pixels.
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FIGURE 2 | Transduction efficiency of CAV2-PRSx8-hM3Dq-mCherry viral vector to express hM3Dq in LC. (A) Mean hM3Dq expression in DBH positive cells after
manual cell count. MediumV_1E9 induces the highest level of hM3Dq expression compared to LowV_5E9, MediumV_10E9, and HighV_20E9. MediumV_0.1E9
condition shows similar levels, significantly higher compared to LowV_5E9 and HighV_20E9. (B) Mean aspecific hM3Dq expression. In the MediumV_0.1E9 condition
the lowest level of aspecific expression is observed compared to LowV_1E9, MediumV_1E9 and MediumV_10E9. GLM negative binomial statistical analysis showed
that the chance of an mCherry + pixels detected outside LC is, respectively, 4.8, 9.1, and 3.9 times higher in the LowV_1E9, MediumV_1E9 and MediumV_10E9
condition compared to MediumV_20E9. Bars represent the mean ± SEM per condition. Pattern inside the bars represent the injected volume: low, 3 × 300 nl = no
pattern; medium, 3 × 600 nl = dotted pattern; high, 3 × 1200 nl = striped pattern. Colors of the bars represent the dilution: undiluted (5,10,20E9 pp) = red; diluted
to 1E9 pp = dark blue; diluted to 0.1E9 pp = light blue. Letters above the bar represent significant difference with the corresponding condition (a: the first bar from
the left, in alphabetical order with the last bar being g). Stars added to the letters indicate the level of significance (*p < 0.05; **p < 0.01, ***p < 0.001).
To assess potential damage induced by the administration of
the CAV2 viral vector and subsequent transduction, differences in
DBH expression and LC size were compared between transduced
and non-transduced hemispheres, since viral vector induced
toxicity can induce cell loss. The DBH+ image (8-bit tiff file)
was split into a transduced- and contralateral non-transduced
site, followed by contrast enhancing using “autothreshold –
default.” “Convert to mask” and “invert” commands to achieve
a black background with white pixels. “Analyze particles tool”
was used to select and encircle a cluster of white pixels and
calculate the total area in pixels2 representing the size of
both transduced and contralateral non-transduced LC. The size
of both transduced and contralateral non-transduced LC was
normalized to the average of the contralateral non-transduced
LC within the animal (three sections) (%). Significant decreases
in the size of the transduced LC compared to its contralateral
non-transduced LC due to cell loss were interpreted as signs
of toxicity (Thomas et al., 2001; Reimsnider et al., 2007;
Sen et al., 2014).
Statistical Analysis
Statistical analysis was performed using SPSS statistics 27 (IBM
corporation, Armonk, New York, United States) and Graphs
were made in Graphpad Prism 6. To compare LC-specific
expression between conditions, the fraction of DBH+ cells
expressing hM3Dq were fitted into a random effects linear
mixed model as dependent variable with injection condition as
fixed factor. The individual sections were selected as random
intercept and variance components as covariance structure. Since
the aspecific expression data is unbound and overdispersion
is present, a generalized mixed model with negative binomial
log link and with random intercept for animal ID was fitted
to the data. The number of aspecific mCherry pixels was set
as dependent variable with the log transformed all mCherry+
pixels as offset and the injection condition as fixed effect.
To determine whether there was a significant difference in
size of the transduced LC compared to the contralateral
non-transduced LC per condition, a linear mixed model was
performed with the normalized size as dependent variable, the
condition and the side (transduced or non-transduced) and
interaction as fixed factors and individual section as intercept.
A significant decrease in transduced LC compared to its
contralateral non-transduced LC was interpreted as toxicity.
All data are represented as mean ± standard error of the
mean. A p-value of < 0.05 was required for rejection of the
null hypothesis.
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FIGURE 3 | Graphical representation of the size of the transduced LC
compared to the contralateral non-transduced LC. A significant decrease in
size was observed in all undiluted conditions with the highest decrease in the
MediumV_10E9 condition (transduced LC was 38.5 ± 6.7% of the
contralateral LC size, p < 0.001). A significant decrease in size of transduced
LC was also observed in the LowV_5E9 (77.2 ± 6.7, p = 0.002) and
HighV_20E9 (66.4 ± 7.9, p < 0.001) condition. Bars represent the mean
difference in LC size ± SEM per condition normalized to the contralateral
non-transduced LC (represented by dotted line). Pattern inside the bars
represent the injected volume: low, 3 × 300 nl = no pattern; medium,
3 × 600 nl = dotted pattern; high, 3 × 1,200 nl = striped pattern. Colors of
the bars represent the dilution: undiluted (5,10,20E9 pp) = red; diluted to




In all but four animals (n = 1 of LowV_0.1E9 group, n = 1
of LowV_1E9, n = 1 of MediumV_10E9 group, n = 1 of
MediumV_1E9 group), clear hM3Dq expression was present in
the soma and axonal projections of LC neurons (Figure 1).
In only 6/13 (46%) of the bilaterally injected animals, bilateral
expression of hM3Dq expression was observed, possibly due
to off-target administration (Supplementary Figure 1, injection
tract visible; Rorabaugh et al., 2017).
The fraction of LC neurons expressing hM3Dq was highest
in the MediumV_1E9 condition (87.3 ± 9.8%) and significantly
different from the LowV_5E9 (44.9 ± 8.3%, p = 0.002),
MediumV_10E9 (59.8 ± 8.3%, p = 0.041), and HighV_20E9
group (45.5 ± 9.8%, p = 0.005). MediumV_0.1E9 group
(77.2 ± 5.9%) has significant higher expression compared to the
LowV_5E9 (44.9 ± 8.3%, p = 0.018) and HighV_20E9 group
(45.5± 9.8%, p = 0.029; Figure 2A).
A generalized mixed negative binomial model estimates
the rate of aspecific hM3Dq expression in the LowV_1E9
(18.9 ± 7.6%) and MediumV_1E9 condition (36.2 ± 17.3%) to
be 4.8 times (95%CI 1.4–16.4, p = 0.014) and 9.1 times (95%CI
2.4–34.7, p = 0.001) higher compared to the MediumV_0.1E9
condition (4.0 ± 1.9%), showing the lowest levels of aspecificity.
The aspecific expression in the MediumV_10E9 condition
(15.5 ± 6.3%) is estimated to be 3.9 times higher (95%
CI 1.1 −13.5, p = 0.031) compared to the MediumV_0.1E9
condition (4.0 ± 1.9%) (Figure 2B and Supplementary Table 1
Fixed coefficients).
Signs of Toxicity
Conditions with the highest number of viral particles were
associated with a clear difference in DBH expression and
size of the transduced LC compared to the contralateral LC.
Quantitative comparison of transduced versus contralateral
non-transduced LC size showed a significant size reduction
in these conditions. Toxicity was significantly high in the
MediumV_10E9 condition (p < 0.001), showing a significant
decrease in the size of the transduced LC compared to its
contralateral LC. The size of injected LC was 38.5 ± 6.7%
of the contralateral LC volume. A significant reduction in
size of transduced LC was also observed in the LowV_5E9
(77.2 ± 6.7%; p = 0.002) and HighV_20E9 (66.4 ± 7.9%;
p < 0.001) conditions compared to the contralateral non-
transduced LC (Figure 3). Qualitative analysis of tissue sections
from the MediumV_10E9 and HighV_20E9 condition showed
additionally to decreased LC size, ectopic DBH expression in
the transduced brainstem and clear lesions in the injected
LC (Figures 1A,B MediumV_10E9, HighV_20E9; Figure 4).
Qualitative analysis of the bilaterally hM3Dq expressing animals
did not show clear visible signs of toxicity in the LowV_0.1E9,
LowV_1E9 and MediumV_0.1E9 condition as confirmed by
quantitative analysis of the unilateral expressing animals of these
groups (Representative image Supplementary Figure 2).
DISCUSSION
This study evaluated different conditions for injection of CAV2
viral vector to obtain expression of hM3Dq DREADD in a
high number of LC neurons with limited aspecific expression
and toxicity.
All conditions resulted in hM3Dq expression in LC
noradrenergic neurons but differences in expression specificity
and toxicity were observed. Transduction levels are the highest
when diluted conditions, 0.1E9 pp and 1E9 pp of CAV2-PRSx8-
hM3Dq-mCherry at the target site, are used with average
expression ranging from 67.9 ± 8.3 to 87.3 ± 9.8%. This is
much higher compared to our previous AAV2/7 approach
(20.6 ± 2.3%; 5.99 × 109 GC/µl) (Stevens et al., 2020) and
similar to other groups using the CAV2 viral vector to induce
expression of Channelrhodopsin under control of a PRSx8
promotor at conditions similar to ours (3 injections of 400nl,
a total of 109 viral particles at the target site) observing
expression levels of 83 ± 3.4% (Hayat et al., 2020). Low
expression levels of hM3Dq were observed with the highest
numbers of viral particles (>1E9 pp). A similar decrease in
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FIGURE 4 | Representative section visualizing signs of toxicity. (A) A clear difference in size of the transduced LC (right, encircled) compared to contralateral in
animal injected with MediumV_10E9 condition. Only cell nuclei (DAPI, blue) and DBH+ neurons (primary antibody anti-DBH, AF 488, green) are visualized in this
image. (B) A clear decrease in number of LC neurons, in combination with the presence of lesions and vacuoles (indicated by the white arrows). LC-NA neurons and
projections are visualized using primary anti-DBH antibody (green, AF 488 nm) and expression of hM3Dq DREADD is visualized using anti-RFP (red, AF 594 nm), cell
nuclei are stained with DAPI (blue). Scale bar left image 1,000 µm and right image 100 µm.
expression levels associated with increasing titers have been
described upon pontospinal injections of AAV for retrograde
labeling of noradrenergic neurons (Howorth et al., 2009) and
after injections of an adenovirus vector in striatum (Thomas
et al., 2001). Injection of high viral vector titers can result in
blood-brain barrier changes and leakage of viral particles in
systemic circulation as observed after AAV injection in the
substantia nigra of mice, resulting in lower expression levels
(Van der Perren et al., 2011). Injecting more than 1E9 CAV2
particles also resulted in signs of toxicity with decreased size
of LC, ectopic DBH expression and the presence of lesions.
Excess load of viral particles can induce cellular stress and
disrupt the homeostasis of the endoplasmatic reticulum (ER).
Once ER stress is induced, and proteins do not properly fold,
the unfolded protein response (UPR) pathways are activated
to restore the cellular machinery. This includes activation of
immune pathways with recruitment of macrophages, astrocytes
and microglia and infiltration of antigen non-specific T cells.
These immune response can result in clearance of viral particles
as well as substantial loss of astrocytes and neurons (Thomas
et al., 2001; Reimsnider et al., 2007). Additionally, when a
point of no return is reached, UPR will induce apoptosis and
autophagy leading to cell loss (Sen et al., 2014). Next to high
presentation of viral proteins and transgene, high levels of
the PRSx8 promotor might also induce changes in LC-NA
physiology due to sequestration of Phox2 proteins at the multiple
Phox2 binding sites in the promotor sequence. These proteins
are necessary for maintaining normal NA phenotype, possibly
explaining changes in DBH expression and even cell loss
(Hwang et al., 2005). Although the ectopic DBH expression was
only observed in animals injected with high titer conditions,
we cannot rule out that this phenomenon is possibly due to
non-specific binding of the antibody to compromised cells
(Buchwalow et al., 2011).
The CAV2 viral vector, a non- human derived viral vector,
is described to be safer in use for long-term experiments and
eventual translation to the clinic, due to the absence of a pre-
existing immune response (Kremer et al., 2000; Del Rio et al.,
2019), however, our observations indicate that the use of high
titers of CAV2-PRSx8-hM3Dq-mCherry can induce signs of
toxicity with tissue damage and concurrent lower transduction
efficiency potentially due to a combination of innate immune
responses, cellular stress and phox2 protein sequestration
(Thomas et al., 2001; Hwang et al., 2005; Sen et al., 2014).
Although injecting 1E9 CAV2 particles (MediumV_1E9
condition) did not result in LC damage, a significant presence
of aspecific hM3Dq expression (36.2 ± 17.3%) was observed. By
further reducing the number of injected CAV2 particles to 0.1E9,
efficient transduction of LC neurons was preserved (>70%) while
aspecific expression was significantly reduced to levels below 5%
in the MediumV_0.1E9 and LowV_0.1E9 condition. Previous
studies using the CAV2 viral vector to induce PRSx8-driven
expression of ChR2, PSAM and GtACR2 reported comparably
low levels of aspecific expression (0–2%) (Hickey et al., 2014;
Hirschberg et al., 2017; Xiang et al., 2019; Hayat et al., 2020).
Viral vectors (both AAV and CAV2) containing PRSx8 driven
plasmids are widely used and validated to induce selective
transduction in noradrenergic neurons both in mice and rats
(Vazey and Aston-Jones, 2014; Fortress et al., 2015; Li et al., 2016;
Hirschberg et al., 2017; Kane et al., 2017; Rorabaugh et al., 2017;
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Vazey et al., 2018; Cope et al., 2019; Xiang et al., 2019; Hayat
et al., 2020). In a previous study, using AAV2/7 viral vector to
transduce cells with the PRSx8-hMD3q-mCherry construct, we
observed low levels of hM3Dq expression in LC (20.6 ± 2.3%)
with high levels of aspecific expression (26.0 ± 4.1%) outside
the LC (Stevens et al., 2020). These observations indicate
that CAV2 is a more efficient tool than AAV2/7 to introduce
genes in LC neurons and that PRSx8 can result in important
leakage of expression in non-catecholaminergic neurons. The
latter effect is thought to be (partially) mediated by Phox2
regulatory elements in the promotor sequence activated by Phox2
transcription factors also present in non-catecholaminergic
neurons (Hwang et al., 2001; Bruinstroop et al., 2012). In our
study, off-target hM3Dq expression was assessed using pixel
values instead of manually counting mCherry+/DBH− cells. To
quantify aspecific expression levels in a similar fashion as the
cell-specific hM3Dq levels quantification, confocal images of the
entire section should be acquired to detect any possible off-
target expression and provide the ability for manual cell counting.
As aspecific expression was not the primary hypothesis of this
study resulting in the lack of confocal image data outside of the
LC region, quantification of the DBH−/mCherry+ pixels of the
epifluorescence whole section images served as a valid proxy for
off-target expression.
In a subset of the injected animals no expression was observed
(four in total) and in a subset of bilaterally injected animals
unilateral expression was observed, possibly due to off-target
administration, similar to other studies describing the difficulties
of targeting a small brainstem nucleus and observing unilateral
expression after bilateral LC administration of the viral vector
(Kane et al., 2017; Rorabaugh et al., 2017). Animals with bilateral
hM3Dq expression could not be included for quantitative
analysis of toxicity. In these animals of the LowV_0.1E9,
LowV_1E9, and MediumV_0.1E9 conditions qualitative analysis
did not show major signs of toxicity as observed with the high
titer conditions.
Our results indicate that introducing a new genetic product
into a target region using viral vectors should be approached with
caution and thorough titration with control for toxicity. A few
papers describe these phenomena after injection of adenoviral
or adeno-associated viral vectors, however, not much is reported
about CAV2 (Thomas et al., 2001; Reimsnider et al., 2007; Sen
et al., 2014). Since the use of CAV2 viral vectors in future clinical
trials is considered because of its known advantages such as high
tropism for neurons, ability for retrograde transport and lack
of existing immune response in patients (Kremer et al., 2000;
Junyent and Kremer, 2015; Del Rio et al., 2019), further research
including its safety at higher titers is necessary.
We conclude that direct injection of 0.1E9 CAV2-PRSx8-
hM3Dq-mCherry viral vector particles in LC of adult rats is a
suitable approach for near complete transduction of LC neurons
while keeping aspecific expression and toxicity low. This will
allow future chemogenetic modulating of LC to unravel its role
in regulating the excitability brain networks and in specific
neurological diseases.
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